Navigation Links
Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
Date:10/10/2007

A group of Israeli scientists from the Technion Israel Institute of Technology, the Weizmann Institute of Science and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis patients to the drug Copaxone®. These findings may contribute to the development of personalized medicine for multiple sclerosis sufferers.

Copaxone® was the first original Israeli drug to be approved by the U.S. Food and Drug Administration (FDA), and is today marketed in over 40 countries worldwide, including the U.S.A., Europe, Australia, Latin America and Israel.

The drug molecule was the fruit of research by Prof. Michael Sela, Prof. Ruth Arnon and Dr. Dvora Teitelbaum of the Weizmann Institutes Immunology Department. It was developed for the treatment of multiple sclerosis (MS) by Teva, which produces and markets Copaxone® today.

'Until now, medical treatments for all kinds of diseases have relied on trial and error methods to determine dosage and treatment protocols,' says Prof. Ariel Miller of the Ruth and Bruce Rappaport Faculty of Medicine at the Technion, and Head of the Multiple Sclerosis and Brain Research Center, Carmel Medical Center, Haifa. 'But the process of fixing the correct dosage affects the efficacy of the treatment and can lead to complications in some cases.' In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences. Finding medications and doses to suit the genetic make-up of each individual patient is likely to be more successful and to cause fewer side effects.

The new research, which deals with the genetic components of the response to Copaxone®, was recently published in the journal Pharmacogenetics and Genomics. It represents a significant step toward realizing this medical vision. In the collaborative study, Teva supplied DNA
'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Page: 1 2

Related biology news :

1. Israeli scientists successfully transplant frozen-thawed ovaries in sheep
2. Wisconsin scientists grow critical nerve cells
3. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
4. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
5. UAB scientists discover the origin of a mysterious physical force
6. Fox Chase Cancer Center scientists identify immune-system mutation
7. Scientists Replicate Hepatitis C Virus in Laboratory
8. Scientists detect probable genetic cause of some Parkinsons disease cases
9. Scientists find missing enzyme for tuberculosis iron scavenging pathway
10. Scientists seek answers on what activates deadly anthrax spores
11. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... STATION Researchers at Texas A&M University have confirmed for ... off the Texas coast for at least the past 23 ... to marine life in the area. Steve DiMarco, associate ... dead zones in the Gulf of Mexico for more than ...
... fresh evidence that urbanization in the United States threatens the ... six-year study also refutes one of the most widely accepted ... kinds of birds. Most ecologists have assumed that common ... and raccoons were destroying eggs or killing young birds ...
... Md., April 1, 2008 The U.S. Pharmacopeial (USP) ... dissolution variability of USP Prednisone Lot P Reference Standard ... less variability in USP Prednisone Lot P tablets than ... dosage forms plays a critical role in drug manufacturing ...
Cached Biology News:Researchers confirm dead zone off Texas coast since 1985 2Some migratory birds can't find success in urban areas, study finds 2Some migratory birds can't find success in urban areas, study finds 3Prednisone tablets less variable than marketed drugs 2
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 /PRNewswire/ ... next-generation antibiotics, today announced positive top-line results from ... lead drug candidate MRX-I. MRX-I is an oral ... as MRSA and VRE, while offering physicians and ... than currently available oxazolidinone agents. ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s a new treatment option for excessive menstrual bleeding ... new FDA approved system in the last 14 years, and the only endometrial ablation ... bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... July 21, 2011 The U.S. Food & Drug ... a clinical trial for gene therapy for a rare ... and London, this trial based on preclinical research performed ... gene therapy product, is now going to be launched ...
... July 21, 2011 Advanced Cell Technology, Inc. ("ACT"; ... medicine, announced today that it has entered into an ... Biotech"), a leading South Korea-based biotechnology company, designed to ... venture, Stem Cell & Regenerative Medicine International (SCRMI).  Under ...
... DURHAM, N.C. Researchers at Duke University Medical Center ... of Chlamydia , the bacteria responsible for the ... States. The team, which included Duke University ... the bacteria,s self-defense mechanisms. The therapies that ...
Cached Biology Technology:Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 2Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 3Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 4Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 5ACT Obtains Exclusive License for Hemangioblast Technology in North America 2ACT Obtains Exclusive License for Hemangioblast Technology in North America 3ACT Obtains Exclusive License for Hemangioblast Technology in North America 4ACT Obtains Exclusive License for Hemangioblast Technology in North America 5Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: